|
|
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1 babyqiqi: ½ð±Ò+10, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸ 2014-08-01 07:53:04 oven1986: ¼ìË÷EPI+1, ¸ÐлӦÖú£¡ 2014-08-01 10:18:29
×÷Õß: Cao, S (Cao, Shuang); Zhou, XB (Zhou, Xin-Bo); Zhang, H (Zhang, Heng); Li, S (Li, Song); Zhong, W (Zhong, Wu)
±êÌâ: Novel cross-link breaker based on zwitterion structure: Synthesis, structure and druggability studies
À´Ô´³ö°æÎï: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
¾í: 68
Ò³: 89-95
DOI: 10.1016/j.ejmech.2013.07.033
³ö°æÄê: OCT 2013
ÕªÒª: It has been universally acknowledged that the increase in cardiac and vascular stiffness is due to the formation of advanced glycosylation end-products (AGEs). Research on the stable form of 3-(carboxymethyl)-4-methylthiazol bromide sodium salt (C6H7BrNNaO2S) showed that it had a notable effect on breaking the AGEs. Two compounds with novel structures, zwitterionic 3-(carboxymethyl)-4-methylthiazol (C6H7O2NS) and a dipolymer (C12H15O4N2S2Br) complex, were obtained. When compared with the forms of sodium salt and dipolymer, zwitterion had an obvious advantage in stability, solubility, synthesis and pH, which made the zwitterion a promising drug. The structure of sodium salt, dipolymer and zwitterion was comparatively analyzed by such methods as single crystal X-ray diffraction, ESI-MS, H-1 NMR, FT-IR and in situ IR. (C) 2013 The Authors. Published by Elsevier Masson SAS. All rights reserved.
Web of Science ºËÐĺϼ¯ÖÐµÄ "±»ÒýƵ´Î": 0
ÔÚ BIOSIS Citation Index Öеı»ÒýƵ´Î: 0
ÔÚÖйú¿ÆÑ§ÒýÎÄÊý¾Ý¿âÖеı»ÒýƵ´Î: 0
SciELO Citation Index ÖÐµÄ "±»ÒýƵ´Î": 0
±»ÒýƵ´ÎºÏ¼Æ: 0
ISSN: 0223-5234; 1768-3254
Èë²ØºÅ: WOS:000326902300010 |
|